Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Akhtar, Javed ^a   Wang, Zhou ^a   Zhang, Zhi P ^a   Bi, Ming M ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Gastric cancer; Lentivirus; shRNA; Stathmin1

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CARCINOGENICITY; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN MKN 45; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STATHMIN 1 GENE; STOMACH CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; LENTIVIRUS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATHMIN; STOMACH NEOPLASMS; TRANSDUCTION, GENETIC; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883766063     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-212     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ward E, Ferlay J, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Parkin D. International variation. Oncogene 2004, 23:6329-6340. 10.1038/sj.onc.1207726, 15322508.
3. Parkin D, Bray F, Devesa S. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37(Suppl 8):S4-S664.
4. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009, 472:467-477. 10.1007/978-1-60327-492-0_23, 19107449.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M. Cancer statistics. CA Cancer J Clin 2006, 56:106-130. 10.3322/canjclin.56.2.106, 16514137.
6. Hudler P. Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012, 2012:761909. 3353315, 22606061.
7. Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction. Trends Biochem Sci 1991, 16:301-305.
8. Doye V, Gouvello SL, Dobransky T. Expression of transfected stathmin cDNA reveals novel phosphorylated forms associated with developmental and functional cell regulation. Biochem J 1992, 287:549-554. 1133199, 1445213.
9. Luo X-N, Mookerjee B, Ferrari A, Mistry S, Atweh G. Regulation of phosphoprotein p18 in leukemic cells. J Biol Chem 1994, 269(14):10312-10318.
10. Bieche I, Lachkar S, Becette V. Overexpression of the Stathmin gene in a subset of human breast cancer. Br J Cancer 1998, 78(6):701-709. 10.1038/bjc.1998.565, 2062973, 9743287.
11. Jeon T, Han M, Lee Y. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010, 102:710-718. 10.1038/sj.bjc.6605537, 2837578, 20087351.
12. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000, 83:311-318. 10.1054/bjoc.2000.1264, 2374559, 10917544.
13. Chen G, Wang H, Gharib T, Huang C, Thomas D, Shedden K, Kuick R, Taylor J, Kardia S, Misek D. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003, 2:107-116. 10.1074/mcp.M200055-MCP200, 12644570.
14. Melhem R, Strahler J, Hailat N, Zhu X, Hanash S. Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun 1991, 179:1649-1655. 10.1016/0006-291X(91)91764-4, 1930203.
15. Friedrich B, Gronberg H, Landstrom M, Gullberg M, BergBh A. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 1995, 27:102-109. 10.1002/pros.2990270207, 7638082.
16. Akhtar J, Wang Z, Yu C, Zhang ZP, Bi MM. STMN-1 gene: a predictor of survival in stage IIA esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy?. Ann Surg Oncol 2013, Epub ahead of print.
17. Elbashir MS, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001, 15:188-200. 10.1101/gad.862301, 312613, 11157775.
18. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008, 8:1461-1470. 10.1586/14737140.8.9.1461, 18759697.
19. Kuo M-F, Wang H-S, Kuo Q-T, Shun C-T, Hsu H-C, Yang S-H, Yuan R-H. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr 2009, 4:74-80. 10.3171/2009.2.PEDS08287, 19569914.
20. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, et al. Overexpression of stathmin in oral squamous-cell carcinoma:correlation with tumour progression and poor prognosis. Br J Cancer 2006, 94(5):717-723. 2361217, 16495930.
21. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 1(104):7564-7569.
22. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, Schmitt M, Lesche R, Maier S, Timmermans M, et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008, 110:317-326. 10.1007/s10549-007-9724-3, 17874182.
23. Lin W-C, Chen S-C, Hu F-C, Chueh S-C, Pu Y-S, Yu H-J, Huang K-H. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2009, 74:1264-1269. 10.1016/j.urology.2009.04.088, 19800106.
24. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 1(115):2453-2463.
25. Chen J, Abi-Daoud M, Wang A, Yang X, Zhang X, Feilotter H, Tron V. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2012, 10:1038.
26. Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 2009, 135:837-846. 10.1007/s00432-008-0520-1, 19034510.
27. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS, Vandenput I, Amant F, , et al. MoMaTec Study Group Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011, 17:3368-3377. 10.1158/1078-0432.CCR-10-2412, 21242118, MoMaTec Study Group.
28. Sherbet GV, Cajone F. Stathmin in cell proliferation and cancer progression. Cancer Genomics & Proteomics 2005, 2:227-238.
29. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 2011, 15:1249-1266. 10.1517/14728222.2011.620951, 21978024.
30. Mistry S, Atweh G. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 2002, 69:299-304.
31. Manjunath N, Wu H, Subramanya S, Shankar P. Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 2009, 61:732-745. 10.1016/j.addr.2009.03.004, 2789654, 19341774.
32. Guo X, Wang W, Hu J, Feng K, Pan Y, Zhang L, Feng Y. Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo. Anat Rec (Hoboken) 2012, 295:2114-2121.
33. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer 2011, 47:2353-2363. 10.1016/j.ejca.2011.05.006, 21680174.
34. Pozzi V, Sartini D, Morganti S, Giuliante R, Ruscio GD, Santarelli A, Rocchetti R, Rubini C, Tomasetti M, Giannatempo G, et al. RNA-mediated gene silencing of nicotinamide N-Methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One 2013, 8:e71272. 10.1371/journal.pone.0071272, 3749215, 23990942.
35. Abbas-Terki T, Blanco-Bose W, Déglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002, 13:2197-2201. 10.1089/104303402320987888, 12542850.
36. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen ISY, Hahn WC, Sharp PA, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003, 9:493-501. 10.1261/rna.2192803, 1370415, 12649500.
37. Koutsilieri E, Rethwilm A, Scheller C. The therapeutic potential of siRNA in gene therapy of neurodegenerative disorder. J Neural Transm 2007, 72:43-49. 43-49.
38. Gaither A, Iourgenko V. RNA interference technologies and their use in cancer research. Curr Opin Oncol 2007, 19:50-54. 10.1097/CCO.0b013e328011a8b0, 17133112.
39. Jeha S, Luo X-N, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996, 56:1445-1450.
40. Centerwatch Drugs approved by the FDA 2007, http://www.centerwatch.com/patient/drugs/druglist.html. Accessed May 8, 2007, Centerwatch.